Exagen (XGN) Equity Ratio (2018 - 2026)

Exagen has reported Equity Ratio for 9 years, with the latest figure at 0.28 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 74.8% year-over-year to 0.28; the trailing twelve-month figure through Mar 2026 stood at 0.28 (up 74.8% YoY), and the FY2025 full-year result was 0.3, up 40.87% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.28, down from 0.3 in the prior quarter.
• The five-year high for Equity Ratio was 0.62 in Q1 2022, with the low at 0.16 in Q1 2025.
• Historically, Equity Ratio has averaged 0.39 across 5 years, with a median of 0.39 in 2024.
• Annual changes were most pronounced in 2025 — Equity Ratio sank 59.61% — and 2026, when it surged 74.8%.
• Exagen's Equity Ratio stood at 0.49 in 2022, then retreated by 19.07% to 0.4 in 2023, then sank by 46.43% to 0.21 in 2024, then soared by 40.87% to 0.3 in 2025, then fell by 7.64% to 0.28 in 2026.
• The last three Equity Ratio figures came in at 0.28 (Q1 2026), 0.3 (Q4 2025), and 0.29 (Q3 2025), per Business Quant data.